Last reviewed · How we verify
dexmedetomidine as adjuvant to bupivacaine
dexmedetomidine as adjuvant to bupivacaine is a Small molecule drug developed by Ain Shams University. It is currently FDA-approved. Also known as: adjuvants to local anesthetics.
At a glance
| Generic name | dexmedetomidine as adjuvant to bupivacaine |
|---|---|
| Also known as | adjuvants to local anesthetics |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Continuous Epidural With Dexmedetomidine Adjuvant in Gynecologic Laparotomy (PHASE4)
- Comparison Between Dexamethasone and Dexmedetomidine in Spinal Anesthesia for Cases With Fracture Pelvis Fixation (EARLY_PHASE1)
- Effect of Dexmedetomidine Versus Dexamethasone as Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block on Postoperative Analgesia in Myasthenic Patients Undergoing Thoracoscopic Thymectomy (NA)
- Dexmedetomidine as an Adjuvant to Bupivacaine in Bilateral PECs for Pain Control After Cardiac Surgeries (PHASE4)
- Dexmedetomidine and Dexamethasone Added as Adjuvant Infraclavicular Brachial Plexus Block in Upper Limb Surgery
- Dexamethasone vs Dexmedetomidine in Sphenopalatine Ganglion Block for Rhinoplasty Pain (PHASE1)
- Comparative Analysis of Intraoperative Effect Dexmedetomidine and Fentanyl as an Adjuvant to Heavy Bupivacaine in Spinal Anaesthesia in Lower Limb Orthopedic Surgeries to Evaluate the Hemodynamic Stability and Onset and Duration of Motor Block of Using Intrathecal Dexmedetomidine and Fentanyl (PHASE4)
- Ultrasound-Guided Infraclvicular Block Using Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Upper Limb Orthopedic Surgery (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dexmedetomidine as adjuvant to bupivacaine CI brief — competitive landscape report
- dexmedetomidine as adjuvant to bupivacaine updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about dexmedetomidine as adjuvant to bupivacaine
What is dexmedetomidine as adjuvant to bupivacaine?
dexmedetomidine as adjuvant to bupivacaine is a Small molecule drug developed by Ain Shams University.
Who makes dexmedetomidine as adjuvant to bupivacaine?
dexmedetomidine as adjuvant to bupivacaine is developed and marketed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).
Is dexmedetomidine as adjuvant to bupivacaine also known as anything else?
dexmedetomidine as adjuvant to bupivacaine is also known as adjuvants to local anesthetics.
What development phase is dexmedetomidine as adjuvant to bupivacaine in?
dexmedetomidine as adjuvant to bupivacaine is FDA-approved (marketed).
Related
- Manufacturer: Ain Shams University — full pipeline
- Also known as: adjuvants to local anesthetics
- Compare: dexmedetomidine as adjuvant to bupivacaine vs similar drugs
- Pricing: dexmedetomidine as adjuvant to bupivacaine cost, discount & access